# A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma

> **NCT07030517** · PHASE4 · RECRUITING · sponsor: **Johnson & Johnson Private Limited** · enrollment: 75 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Teclistamab

## Key facts

- **NCT ID:** NCT07030517
- **Lead sponsor:** Johnson & Johnson Private Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-22
- **Primary completion:** 2026-11-03
- **Final completion:** 2027-06-20
- **Target enrollment:** 75 (ESTIMATED)
- **Last updated:** 2026-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07030517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07030517, "A Study to Assess Safety of Teclistamab in Indian Participants With Relapsed and Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07030517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*